Product Image

Contributor Information

  • Name Ayham Alnabulsi
  • Institute Vertebrate Antibodies Limited

Tool Details

  • Tool name: Anti-Cytochrome P450 1B1 [5D3]
  • Alternate names: Aryl hydrocarbon hydroxylase antibody, CP1B antibody, CP1B1_HUMAN antibody, Cyp1b1 antibody, CYPIB1 antibody, Cytochrome P45 1B1 antibody, Cytochrome P45 family 1 subfamily B polypeptide 1 antibody, Cytochrome P45 subfamily I (dioxin inducible) polypeptide 1 (glaucoma 3 primary infantile) antibody, Flavoprotein linked monooxygenase antibody, GLC3A antibody, Microsomal monooxygenase antibody, P451B1 antibody, Xenobiotic monooxygenase antibody
  • Clone: 5D3
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Cancer type: Genitourinary cancer; Gynaecologic cancer; Breast cancer
  • Application: ELISA ; IHC ; WB
  • Strain: Balb/c
  • Description: Monoclonal antibody directed against CYP1B1, a possible anti-cancer target.
  • Immunogen: Ovalbumin-conjugated synthetic peptide; PENFDPARFLDKDGL (aa. 437-451). Peptide immunogen is identical in mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis familiaris), pig (Sus scrofa) and horse (Equus caballus).
  • Immunogen UniProt ID: Q16678
  • Isotype: IgG1 kappa
  • Research area: Cancer; Tissue-specific biology; Cell signaling and signal transduction; Metabolism; Neurobiology
  • Myeloma used: P3X63Ag8.653

  • For Research Use Only

Target Details

  • Target: Human cytochrome P450 1B1
  • Target background: Cytochrome P450 (CYP) 1B1 is overexpressed in tumour cells and is recognised as a biomarker of the tumour phenotype. Cytochrome P450 1B1 (CYP1B1) is active in the metabolism of oestrogens to reactive catechols and of different procarcinogens. The cytochrome P450 proteins are monooxygenases which catalyse many reactions involved in drug metabolism and the synthesis of cholesterol, steroids and other lipids. Recent studies have highlighted the potential of this enzyme as a novel cancer therapeutic target, resulting in several clinical development programs focused on CYP1B1-activated prodrugs and CYP1B1 inhibitors.

Application Details

  • Application: ELISA ; IHC ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20°C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4°C

Documentation

Related Tools

Product Image

Anti-CD23 [5E3]

#154770
Product Image

Anti-RA056/11.76.1 [11.76.1]

#160523
Product Image

Anti-BCL2 [bcl-2/100] mAb

#151406

References

  • •  Carnell et al. 2004. Int J Radiat Oncol Biol Phys. 58(2):500-9. PMID: 14751521.
  • •  Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue.
  • •  Maecker et al. 2003. Blood. 102(9):3287-94. PMID: 12869499.
  • •  The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells.
  • •  McFadyen et al. 2001. Br J Cancer. 85(2):242-6. PMID: 11461084.
  • •  Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer.
  • •  Murray et al. 2001. Annu Rev Pharmacol Toxicol. 41:297-316. PMID: 11264459.
  • •  Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1.
  • •  McFadyen et al. 1999. J Histochem Cytochem. 47(11):1457-64. PMID: 10544218.
  • •  Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1.